NASDAQ: GOVX · Life Sciences · 6 alerts · CIK 832489
Share price
$2.02Close, Nov 16
Market cap
$1.1M
Shares outstanding
544.45KLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GeoVax Labs, Inc. filings on SEC EDGAR ↗
GeoVax Labs, Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $17.0 million in the prior year period. The company is prioritizing its GEO-MVA vaccine candidate for poxviruses and its Gedeptin oncology program, though both require additional financing to initiate upcoming Phase 3 and Phase 2 trials, respectively.
GeoVax Labs, Inc. filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-24 reverse stock split of its common stock. The split automatically combines every 24 shares of issued and outstanding common stock into one share, with fractional shares rounded up to the nearest whole number. The action is intended to consolidate the number of outstanding shares without changing the proportional ownership interest of stockholders.
GeoVax Labs appointed Shahin Behroyan to its Board of Directors and named Tyler O’Brien as interim Chief Executive Officer and Chairman of the Board. Mr. Behroyan fills a vacancy following the resignation of five former directors, while Mr. O'Brien will serve as the principal executive officer until a permanent CEO is designated.
GeoVax Labs terminated David A. Dodd as President and Chief Executive Officer for 'Cause' effective November 5, 2026, following his refusal to comply with Board-approved directives. Mr. Dodd remains Chairman of the Board, but the company does not intend to pay him severance or accelerate his stock options due to the 'Cause' determination. The company noted the termination is unrelated to its business operations or financial results.
GeoVax Labs stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-25. Additionally, shareholders approved the issuance of up to 11.4 million shares related to a warrant exercise inducement from August 2026.
GeoVax Labs $1M Debt Financing with Bowery Consulting Group Inc.
GeoVax Labs entered into a $1 million unsecured revolving loan agreement with Bowery Consulting Group to fund general corporate purposes and expenses for a planned public equity offering. The facility carries a 12% interest rate and a one-year maturity. In connection with the agreement, five existing directors resigned and three new independent directors nominated by the lender were appointed to the board.